Skip the Botox and Try One of These Growth Factor Serums Instead

Here, we spoke to experts about the anti-aging benefits of growth factor serums. Shop the 11 best growth factor serums now.

FDA approves Inluriyo for advanced breast cancer

The U.S. Food and Drug Administration has approved Eli Lilly's Inluriyo (imlunestrant), an oral estrogen receptor antagonist, ...
ascopubs.org

Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis ...

NOTE. Percentage values in the cells may not sum up to 100% because of rounding. Bold indicates P < .05. Abbreviations: Bev, bevacizumab; ECOG-PS, Eastern Cooperative Oncology Group Performance Status ...
ascopubs.org

Redefining Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer in the Era of Novel Antibody-Drug Conjugates

Timing and Outcomes of Palliative Care Integration Into Care of Adolescents and Young Adults With Advanced Cancer The advent of next-generation antibody-drug conjugates (ADCs), particularly ...

Ensem Therapeutics Announces ETX-636 Granted Fast Track Designation by the FDA for Advanced Breast Cancer

Ensem Therapeutics, Inc. (ENSEM) today announced the U.S. Food and Drug Administration (FDA) granted Fast Track designation ...

Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee (DSMC) to Accelerate 177Lu-RAD202 Phase 1 ‘HEAT’ Dose Escalation Clinical ...

Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of ...
TipRanks on MSN

Radiopharm receives DSMC recommendation to advance Phase 1 ‘HEAT’ trial

Theranostics announced that it has received a positive recommendation from the Data Safety and Monitoring Committee to advance ...

Debiopharm Licenses SunRock Biopharma’s Anti-HER3/HER2 Antibody to Explore the Full Potential of Bispecific ADC Debio 2512

LAUSANNE, Switzerland & SANTIAGO DE COMPOSTELA, Spain, September 30, 2025--Debiopharm ( a privately-owned, Swiss-based, ...
MPR

Trastuzumab Deruxtecan Superior to T-DM1 in High-Risk HER2+ Early Breast Cancer

The DESTINY-Breast05 trial included patients with HER2-positive primary breast cancer who were at high risk of recurrence and had residual invasive disease in breast or axillary lymph nodes following ...